SCYNEXIS, Inc.
SCYXHealthcare|Medical - Pharmaceuticals|US
$3.50
+0.20 (+6.06%)
Tangible Book / Share
$4.99
Cash / Share
$3.98
About
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Stock Price
-26.6%(1Y)
1M
-17.1%
3M
-33.2%
6M
-52.3%
YTD
-30.8%
1Y
-27.1%
3Y
-76.4%
5Y
-92.2%
Pipeline Summary
18 total trials6
Phase 1
5
Phase 2
7
Phase 3
0
Phase 4
Completed: 16Terminated: 2
Key Facts
Market Cap$22.0M
Employees18 (-36% YoY)
CEODavid Angulo
IPO DateMay 2, 2014
Beta1.15
52-Week Range$3.28 – $9.12
Avg Volume222,969
ExchangeNASDAQ
Websitescynexis.com
Ownership
Float96.5%
Shares Outstanding6.3M
Recent Insider Trades
Burke Steven KeithAWARD
Sep 18, 20265,750 shares
Burke Steven KeithAWARD
Sep 18, 20265,750 shares @ $4.46
Burke Steven KeithOTHER
Sep 18, 20260 shares
Subramanian SanjayAWARD
Sep 9, 2026100,000 shares @ $4.91
Subramanian SanjayOTHER
Sep 9, 20260 shares
Peers
Recent News
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026 · globenewswire.com
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
Oct 29, 2026 · globenewswire.com
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
Oct 22, 2026 · globenewswire.com
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
Oct 21, 2026 · globenewswire.com
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
Oct 7, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:33 AM